ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
133.009,78
0,00%
S&P 500
5.745,37
0,40%
US Dollar vs BRL
5,438
0,00%
Bitcoin
65.450,08
0,41%
Brent Oil
71,345
0,56%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Alto Neuroscience Inc (ANRO)

  7. Alto Neuroscience Inc (ANRO) Notícias

ANRO

Alto Neuroscience (ANRO)

Alto Neuroscience Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:ANRO
DataHoraFonteTítuloCódigoCompanhia
04/09/202409:05Business WireAlto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care AntidepressantsNYSE:ANROAlto Neuroscience Inc
03/09/202409:05Business WireAlto Neuroscience to Participate in Upcoming Investor ConferencesNYSE:ANROAlto Neuroscience Inc
13/08/202417:36Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:ANROAlto Neuroscience Inc
13/08/202417:33Edgar (US Regulatory)Form 8-K - Current reportNYSE:ANROAlto Neuroscience Inc
13/08/202417:05Business WireAlto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business HighlightsNYSE:ANROAlto Neuroscience Inc
25/07/202409:30Business WireAlto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry ApproachNYSE:ANROAlto Neuroscience Inc
16/07/202408:30Business WireAlto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive DisorderNYSE:ANROAlto Neuroscience Inc
11/07/202417:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ANROAlto Neuroscience Inc
20/06/202409:05Business WireAlto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with SchizophreniaNYSE:ANROAlto Neuroscience Inc
18/06/202409:05Business WireAmit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award WinnerNYSE:ANROAlto Neuroscience Inc
29/05/202409:05Business WireAlto Neuroscience to Present at the Jefferies Global Healthcare ConferenceNYSE:ANROAlto Neuroscience Inc
21/05/202409:05Business WireAlto Neuroscience Appoints Michael Hanley as Chief Operating OfficerNYSE:ANROAlto Neuroscience Inc
14/05/202417:03Business WireAlto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business HighlightsNYSE:ANROAlto Neuroscience Inc
09/05/202409:05Business WireAlto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific ConferencesNYSE:ANROAlto Neuroscience Inc
23/04/202409:05Business WireAlto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for SchizophreniaNYSE:ANROAlto Neuroscience Inc
03/04/202409:05Business WireAlto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive DisorderNYSE:ANROAlto Neuroscience Inc
21/03/202417:05Business WireAlto Neuroscience Reports Full Year 2023 Financial Results and Recent Business HighlightsNYSE:ANROAlto Neuroscience Inc
11/03/202409:05Business WireAlto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of DirectorsNYSE:ANROAlto Neuroscience Inc
27/02/202410:00Business WireAlto Neuroscience to Present at the TD Cowen 44th Annual Healthcare ConferenceNYSE:ANROAlto Neuroscience Inc
06/02/202418:05Business WireAlto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesNYSE:ANROAlto Neuroscience Inc
 Apresentando as notícias mais relevantes sobre:NYSE:ANRO

Seu Histórico Recente

BOV
PRIO3
PETRORIO ON
BOV
IBOV
Índice Bovespa
BOV
PDGR3
PDG REALT ON
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
CBEE3
AMPLA ENERG ON
BOV
GFSA3
GAFISA ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados